Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 109581-93-3 Chemical Structure| 109581-93-3

Structure of Tacrolimus monohydrate
CAS No.: 109581-93-3

Chemical Structure| 109581-93-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex that inhibits calcineurin phosphatase, thereby inhibiting T-lymphocyte signal transduction and IL-2 transcription, demonstrating immunosuppressive properties.

Synonyms: FK506 monohydrate; FR900506 monohydrate; Fujimycin monohydrate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tacrolimus monohydrate

CAS No. :109581-93-3
Formula : C44H71NO13
M.W : 822.03
SMILES Code : O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O.O
Synonyms :
FK506 monohydrate; FR900506 monohydrate; Fujimycin monohydrate
MDL No. :MFCD11045918

Safety of Tacrolimus monohydrate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Description
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase. This inhibition leads to the suppression of T-lymphocyte signal transduction and IL-2 transcription, conferring immunosuppressive properties [1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01028716 Acute Biphenotypic Leukemia ... More >> Acute Erythroid Leukemia in Remission Acute Leukemia in Remission Acute Megakaryoblastic Leukemia Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Acute Myeloid Leukemia in Remission Acute Myeloid Leukemia With FLT3/ITD Mutation Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM Acute Myeloid Leukemia With Multilineage Dysplasia Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214 Acute Undifferentiated Leukemia Adult Acute Lymphoblastic Leukemia in Complete Remission B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Burkitt Lymphoma Childhood Acute Lymphoblastic Leukemia in Complete Remission DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma Myelodysplastic Syndrome Recurrent Anaplastic Large Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Secondary Acute Myeloid Leukemia T Lymphoblastic Lymphoma Less << Phase 2 Recruiting - United States, Washington ... More >> VA Puget Sound Health Care System Not yet recruiting Seattle, Washington, United States, 98101 Contact: Thomas Chauncey    206-764-2969    thomas.chauncey@va.gov    Principal Investigator: Thomas Chauncey          Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rachel B. Salit    206-667-1317    rsalit@fredhutch.org    Principal Investigator: Rachel B. Salit Less <<
NCT03602898 Acute Lymphoblastic Leukemia i... More >>n Remission Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Acute Myeloid Leukemia in Remission Blasts 5 Percent or Less of Bone Marrow Nucleated Cells Chronic Myelomonocytic Leukemia Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Donor Minimal Residual Disease Myelodysplastic Syndrome Myelofibrosis Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Less << Phase 2 Not yet recruiting September 17, 2023 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Not yet recruiting Seattle, Washington, United States, 98109 Contact: Masumi Ueda    206-667-4546       Principal Investigator: Masumi Ueda Less <<
NCT00589316 Acute Myeloid Leukemia Arising... More >> From Previous Myelodysplastic Syndrome Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission CD45-Positive Neoplastic Cells Present Chronic Myelomonocytic Leukemia Previously Treated Myelodysplastic Syndrome Refractory Anemia With Excess Blasts Refractory Anemia With Ring Sideroblasts Refractory Cytopenia With Multilineage Dysplasia Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts Less << Phase 1 Active, not recruiting October 1, 2024 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT03467386 Acute Myeloid Leukemia in Remi... More >>ssion Hematopoietic Cell Transplantation Recipient Less << Phase 1 Recruiting June 2020 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Anthony S. Stein, MD    626-256-4673    astein@coh.org    Principal Investigator: Anthony S. Stein, MD Less <<
NCT03128359 Acute Leukemia ... More >> Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Diffuse Large B-Cell Lymphoma Follicular Lymphoma Graft Versus Host Disease Hodgkin Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Myelodysplastic Syndrome Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Secondary Myelodysplastic Syndrome Less << Phase 2 Recruiting June 2019 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Monzr M. Al Malki, MD    626-256-4673    malmalki@coh.org    Principal Investigator: Monzr M. Al Malki, MD Less <<
NCT00789776 Acute Lymphoblastic Leukemia ... More >> Acute Myeloid Leukemia Aggressive Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma Previously Treated Myelodysplastic Syndrome Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Indolent Adult Non-Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Plasma Cell Myeloma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hodgkin Lymphoma Refractory Plasma Cell Myeloma Refractory Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia Less << Phase 1 Phase 2 Active, not recruiting May 18, 2021 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 United States, Wisconsin Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States, 53201 Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT00358657 Immunodeficiency Syndrome ... More >> Non-Cancer Diagnosis Severe Aplastic Anemia Less << Phase 2 Recruiting - United States, Tennessee ... More >> The Children's Hospital at TriStar Centennial Recruiting Nashville, Tennessee, United States, 37203 Contact: Haydar A. Frangoul    615-329-7339    Haydar.Frangoul@hcahealthcare.com    Principal Investigator: Haydar A. Frangoul          Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: James Connelly    615-936-1762    james.a.connelly@vanderbilt.edu    Principal Investigator: James Connelly          United States, Washington Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Lauri M. Burroughs    206-667-2396    lburroug@fredhutch.org    Principal Investigator: Lauri M. Burroughs Less <<
NCT00789776 - Active, not recruiting - -
NCT03712878 Hematopoietic and Lymphoid Cel... More >>l Neoplasm Less << Phase 2 Recruiting December 2021 United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Dolores Grosso, CRNP    215-955-8874    dolores.grosso@jefferson.edu Less <<
NCT03076151 Transplantation ... More >> Kidney Pharmacokinetic Less << Phase 4 Recruiting July 2019 France ... More >> Amiens Picardie University Hospital Recruiting Amiens, France, 80054 Contact: Gabriel Choukroun, MD    +33322455455    Choukroun.Gabriel@chu-amiens.fr    Principal Investigator: Gabriel Choukroun, MD          Limoges University Hospital Recruiting Limoges, France, 87042 Contact: Pierre Marquet, MD    +33555053017    pierre.marquet@unilim.fr    Principal Investigator: Marie Essig, MD          Poitiers University Hospital Recruiting Poitiers, France, 86000 Contact: Antoine Thierry, MD    +33549443415    Antoine.thierry@chu-poitiers.fr    Principal Investigator: Antoine Thierry, MD          Tours University Hospital Recruiting Tours, France, 37000 Contact: Mathias Buchler, MD    +33247473746    mathias.buchler@univ-tours.fr    Principal Investigator: Mathias Buchler, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.22mL

0.24mL

0.12mL

6.08mL

1.22mL

0.61mL

12.16mL

2.43mL

1.22mL

References

 

Historical Records

Categories